List view / Grid view
19 January 2016 | By Philippe Villain-Guillot, CEO, Nosopharm
Philippe Villain-Guillot, CEO, Nosopharm, discusses antimicrobial resistance and the challenges facing antibacterial drug discovery and development...
2 September 2015 | By Victoria White
ESCMID advocates the need for greater education, guidance and research on the build-up, treatment and prevention of biofilms...
22 May 2015 | By Victoria White
Vinpocetine is an effective treatment for middle-ear infections, showing the ability to improve bacterial clearance and reduce hearing loss...
14 May 2015 | By Victoria White
Antibiotic Research UK has welcomed this latest report to come from Jim O’Neill's Review on Antimicrobial Resistance and has endorses its recommendations...
30 April 2015 | By Victoria White
Biotech companies presented new mechanisms and approaches in the global fight against infections in a pipeline session at ECCMID...
3 February 2015 | By Innovative Medicines Initiative (IMI)
Two years after the start of the Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) programme, the first patient has been enrolled into a Phase 2 trial sponsored by MedImmune, the global biologics research and development arm of AstraZeneca. The trial with MEDI4893 is among mechanically ventilated intubated…
2 December 2014 | By BioVersys and Enamine
Enamine Ltd. and BioVersys AG announced the extension of their drug discovery collaboration for the 4th consecutive year...
